NHT Global(NHTC) - 2021 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Total revenue for Q4 2021 was $16.1 million, a decline of 3% compared to $16.6 million in Q4 2020, but an increase of 13% compared to $14.3 million in Q3 2021 [11] - For the full year 2021, total revenue was $60 million, down from $62.1 million in 2020, primarily due to a $5.5 million increase in deferred revenue [11] - Net income for Q4 2021 totaled $232,000 or $0.02 per diluted share, compared to $747,000 or $0.07 per diluted share in Q4 2020 [13] - Full-year net income was $1.1 million or $0.09 per diluted share, compared to $843,000 or $0.07 per diluted share in 2020 [13] Business Line Data and Key Metrics Changes - Order volume increased by 29% compared to Q3 2021 and 20% over Q4 2020, indicating strong demand for products [6] - The company launched a new product, Biotech Trio, which contributed meaningfully to net sales [7][8] Market Data and Key Metrics Changes - In Japan, sales achieved triple-digit growth over both the prior quarter and year-ago period, contributing more than $0.5 million in revenue for Q4 2021 [9] - The company is optimistic about expanding operations in South America, particularly in Peru, Colombia, and Bolivia [9] Company Strategy and Development Direction - The company aims to support its members and grow its business to capitalize on improvements in the operating environment [16] - There is a focus on innovative product releases throughout 2022 to enhance market presence [8] Management's Comments on Operating Environment and Future Outlook - The management expressed guarded optimism about carrying strong momentum into 2022 despite ongoing challenges from the COVID-19 pandemic [16] - The company remains focused on managing controllable elements to improve operational and financial performance [10] Other Important Information - The company maintained a gross profit margin of 74.2% in Q4 2021, down from 75.8% in Q4 2020, but increased to 75% for the full year from 72.6% in 2020 [11][12] - Total cash and cash equivalents were $83.8 million at December 31, 2021, down from $92.4 million at the end of 2020 [14] Q&A Session Summary - No specific questions or answers were documented in the provided content [17]